Distribution of different chemotherapy regimens and 3-y OS estimated by Cox regression analysis in MCL
| . | Nordic MCL2 . | CHOP . | CHOP/cytarabine* . | FC . | Chlorambucil . | Bendamustine . | Other regimens† . | Cytarabine . | CVP . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 324 | 310 | 84 | 43 | 132 | 51 | 57 | 30 | 35 | |||||||||
| Median age, years | 59 | 71 | 70 | 72 | 78 | 72 | 82 | 72 | 77 | |||||||||
| 3-y OS | 79.7% | 51.5% | 59.5% | 53.1% | 39.3% | 58.7% | 28.4% | 55.9% | 22.9% | |||||||||
| N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | |
| Age, years | ||||||||||||||||||
| ≤65 | 259 (79.9) | 81.5 | 58 (18.7) | 66.1 | 13 (15.5) | 66.1 | 6 (14.0) | 66.7 | 14 (10.6) | 34.6 | 4 (7.8) | — | 8 (14.3) | 62.5 | 8 (26.7) | 72.9 | 5 (14.3) | 60.0 |
| >65 | 65 (20.1) | 72.0 | 252 (81.3) | 48.1 | 71 (84.5) | 57.8 | 37 (86.0) | 50.9 | 118 (89.4) | 39.7 | 47 (92.2) | 62.3 | 48 (85.7) | 24.5 | 22 (73.3) | 50.8 | 30 (85.7) | 16.7 |
| Missing | ||||||||||||||||||
| WHO PS | ||||||||||||||||||
| 0-1 | 297 (91.7) | 82.2 | 257 (82.9) | 58.5 | 71 (84.5) | 65.0 | 33 (76.7) | 66.2 | 97 (73.5) | 47.2 | 44 (86.3) | 59.3 | 44 (77.2) | 39.5 | 22 (73.3) | 66.8 | 24 (68.6) | 25.0 |
| 2-4 | 26 (8.0) | 52.6 | 52 (16.8) | 15.5 | 13 (15.5) | 35.9 | 10 (23.3) | 10.0 | 30 (22.7) | 14.7 | 7 (13.7) | 57.1 | 13 (22.8) | — | 8 (26.7) | 25.0 | 11 (31.4) | 18.2 |
| Missing | 1 (0.3) | 1 (0.3) | 5 (3.8) | |||||||||||||||
| MIPI | ||||||||||||||||||
| Low | 93 (28.7) | 87.9 | 19 (6.1) | 83.3 | 8 (9.5) | 72.9 | 1 (2.3) | — | 5 (3.8) | 53.3 | 4 (7.8) | — | 4 (7.0) | 50.0 | 3 (10.0) | 66.7 | 1 (2.9) | — |
| Intermediate | 91 (28.1) | 88.7 | 96 (30.9) | 75.3 | 24 (28.6) | 76.6 | 11 (25.6) | 72.7 | 20 (15.2) | 60.6 | 13 (25.5) | 75.0 | 4 (7.0) | — | 7 (23.3) | 83.3 | 4 (11.4) | 25.0 |
| High | 93 (28.7) | 61.6 | 145 (46.8) | 38.8 | 36 (42.9) | 47.1 | 25 (58.1) | 48.0 | 83 (62.9) | 31.4 | 29 (56.9) | 61.4 | 41 (71.9) | 25.6 | 17 (56.7) | 40.3 | 27 (77.1) | 14.8 |
| Missing | 47 (14.5) | 50 (16.2) | 16 (19.0) | 6 (13.9) | 24 (18.2) | 5 (9.8) | 8 (14.0) | 3 (10.0) | 3 (8.6) | |||||||||
| Rituximab | ||||||||||||||||||
| No | 0 (0) | — | 96 (31.0) | 36.7 | 3 (3.6) | 33.3 | 9 (20.9) | 40.0 | 109 (82.6) | 40.0 | 6 (11.8) | — | 27 (47.4) | 19.6 | 5 (16.7) | — | 13 (37.1) | 23.1 |
| Yes | 324 (100) | 79.7 | 195 (62.9) | 59.4 | 81 (96.4) | 60.5 | 34 (79.1) | 55.9 | 19 (14.4) | 45.0 | 45 (88.2) | 68.2 | 24 (42.1) | 47.2 | 24 (80.0) | 62.3 | 19 (54.3) | 26.3 |
| Missing | 19 (6.1) | 4 (3.0) | 6 (10.5) | 1 (3.3) | 3 (8.6) | |||||||||||||
| Years of diagnosis | ||||||||||||||||||
| 2000-2005 | 117 (36.1) | 81.2 | 181 (58.4) | 49.1 | 21 (25.0) | 47.6 | 19 (44.2) | 73.7 | 77 (58.3) | 31.2 | 0 (0) | — | 32 (56.1) | 25.0 | 8 (26.7) | 50.0 | 13 (37.1) | 23.1 |
| 2006-2011 | 207 (63.9) | 78.8 | 129 (41.6) | 55.4 | 63 (75.0) | 66.4 | 24 55.8) | 36.4 | 55 (41.7) | 54.4 | 51 (100) | 58.7 | 25 (43.9) | 41.8 | 22 (73.3) | 51.6 | 22 (62.9) | 22.7 |
| . | Nordic MCL2 . | CHOP . | CHOP/cytarabine* . | FC . | Chlorambucil . | Bendamustine . | Other regimens† . | Cytarabine . | CVP . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 324 | 310 | 84 | 43 | 132 | 51 | 57 | 30 | 35 | |||||||||
| Median age, years | 59 | 71 | 70 | 72 | 78 | 72 | 82 | 72 | 77 | |||||||||
| 3-y OS | 79.7% | 51.5% | 59.5% | 53.1% | 39.3% | 58.7% | 28.4% | 55.9% | 22.9% | |||||||||
| N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | N (%) | 3-y OS | |
| Age, years | ||||||||||||||||||
| ≤65 | 259 (79.9) | 81.5 | 58 (18.7) | 66.1 | 13 (15.5) | 66.1 | 6 (14.0) | 66.7 | 14 (10.6) | 34.6 | 4 (7.8) | — | 8 (14.3) | 62.5 | 8 (26.7) | 72.9 | 5 (14.3) | 60.0 |
| >65 | 65 (20.1) | 72.0 | 252 (81.3) | 48.1 | 71 (84.5) | 57.8 | 37 (86.0) | 50.9 | 118 (89.4) | 39.7 | 47 (92.2) | 62.3 | 48 (85.7) | 24.5 | 22 (73.3) | 50.8 | 30 (85.7) | 16.7 |
| Missing | ||||||||||||||||||
| WHO PS | ||||||||||||||||||
| 0-1 | 297 (91.7) | 82.2 | 257 (82.9) | 58.5 | 71 (84.5) | 65.0 | 33 (76.7) | 66.2 | 97 (73.5) | 47.2 | 44 (86.3) | 59.3 | 44 (77.2) | 39.5 | 22 (73.3) | 66.8 | 24 (68.6) | 25.0 |
| 2-4 | 26 (8.0) | 52.6 | 52 (16.8) | 15.5 | 13 (15.5) | 35.9 | 10 (23.3) | 10.0 | 30 (22.7) | 14.7 | 7 (13.7) | 57.1 | 13 (22.8) | — | 8 (26.7) | 25.0 | 11 (31.4) | 18.2 |
| Missing | 1 (0.3) | 1 (0.3) | 5 (3.8) | |||||||||||||||
| MIPI | ||||||||||||||||||
| Low | 93 (28.7) | 87.9 | 19 (6.1) | 83.3 | 8 (9.5) | 72.9 | 1 (2.3) | — | 5 (3.8) | 53.3 | 4 (7.8) | — | 4 (7.0) | 50.0 | 3 (10.0) | 66.7 | 1 (2.9) | — |
| Intermediate | 91 (28.1) | 88.7 | 96 (30.9) | 75.3 | 24 (28.6) | 76.6 | 11 (25.6) | 72.7 | 20 (15.2) | 60.6 | 13 (25.5) | 75.0 | 4 (7.0) | — | 7 (23.3) | 83.3 | 4 (11.4) | 25.0 |
| High | 93 (28.7) | 61.6 | 145 (46.8) | 38.8 | 36 (42.9) | 47.1 | 25 (58.1) | 48.0 | 83 (62.9) | 31.4 | 29 (56.9) | 61.4 | 41 (71.9) | 25.6 | 17 (56.7) | 40.3 | 27 (77.1) | 14.8 |
| Missing | 47 (14.5) | 50 (16.2) | 16 (19.0) | 6 (13.9) | 24 (18.2) | 5 (9.8) | 8 (14.0) | 3 (10.0) | 3 (8.6) | |||||||||
| Rituximab | ||||||||||||||||||
| No | 0 (0) | — | 96 (31.0) | 36.7 | 3 (3.6) | 33.3 | 9 (20.9) | 40.0 | 109 (82.6) | 40.0 | 6 (11.8) | — | 27 (47.4) | 19.6 | 5 (16.7) | — | 13 (37.1) | 23.1 |
| Yes | 324 (100) | 79.7 | 195 (62.9) | 59.4 | 81 (96.4) | 60.5 | 34 (79.1) | 55.9 | 19 (14.4) | 45.0 | 45 (88.2) | 68.2 | 24 (42.1) | 47.2 | 24 (80.0) | 62.3 | 19 (54.3) | 26.3 |
| Missing | 19 (6.1) | 4 (3.0) | 6 (10.5) | 1 (3.3) | 3 (8.6) | |||||||||||||
| Years of diagnosis | ||||||||||||||||||
| 2000-2005 | 117 (36.1) | 81.2 | 181 (58.4) | 49.1 | 21 (25.0) | 47.6 | 19 (44.2) | 73.7 | 77 (58.3) | 31.2 | 0 (0) | — | 32 (56.1) | 25.0 | 8 (26.7) | 50.0 | 13 (37.1) | 23.1 |
| 2006-2011 | 207 (63.9) | 78.8 | 129 (41.6) | 55.4 | 63 (75.0) | 66.4 | 24 55.8) | 36.4 | 55 (41.7) | 54.4 | 51 (100) | 58.7 | 25 (43.9) | 41.8 | 22 (73.3) | 51.6 | 22 (62.9) | 22.7 |
In this regimen, cytarabine was given at the dose of 1 g/m2 twice daily, days 1-2 per cycle.
Other regimens: CVIP (cyclophosphamide, etoposide, idarubicine, prednisone), hyper-CVAD (rituximab + fractioned CHOP alternating with rituximab + high-dose methotrexate/cytarabine), “mini-BEAM” (carmustine, etoposide, cytarabine, melphalan), single rituximab, bortezomib, trofosfamide, vincristine, fludarabine, and cyclophosphamide.